吉林省嘉晔信息科技有限公司
20-99人
公司优势
热招职位
相关职位
热门城市
20,861+ 岗位更新等你来订阅
一键订阅最新的岗位，每周送达
🎉恭喜你，订阅成功
继续订阅您可以在邮箱中随时取消订阅
企业性质：微流控技术应用整体解决方案提供商
银方舟是一家集微流控芯片研发与设计、制造与应用于一体的科技服务企业，汇聚众多行业顶尖人才，具备雄厚的软实力。
企业愿景：让中国的微流控走向世界
微流控是一门融合工程学、物理学、化学、微加工和生物工程的多学科交叉技术，提供创新性解决方案，具备显著的成本优势，已在行业内引发广泛关注。“让中国的微流控走向世界”是企业的愿景，也是银方舟持续发展的动力。
企业作风：专注、严谨、开放、创新
银方舟坚持专注、严谨、开放、创新的理念，致力于为客户提供最优质的服务。
企业宗旨：科学、创新、服务
以科学为驱动，以创新为发展，以服务为宗旨，坚持质量优先，独立自主，绿色发展。
银河期货有限公司经中国证券监督管理委员会批准，在国家工商行政管理总局注册，隶属于中国银河金融控股有限责任公司，由中国银河证券股份有限公司控股的专业型金融企业，现注册资本金为12亿元人民币。公司总部位于北京，目前已在北京（3）、上海、深圳、广州、佛山、厦门、福州、哈尔滨、长春、沈阳、大连、济南、青岛、太原、唐山、郑州、南京、杭州、宁波、温州、昆明、西安、成都、重庆、武汉25个重点城市设立27家营业部。
银河期货拥有上海期货交易所、大连商品交易所、郑州商品交易所、中国金融期货交易所全国四家期货交易所的会员资格，可代理国内所有品种的期货交易。银河期货是国内第一家中外合资的期货公司，也是目前唯一一家同时具有著名国内投资银行和国际商业银行股东背景的期货公司。中方股东中国银河证券为其提供强大的业务和网络支持，外方股东苏格兰皇家银行则为其提供独一无二的全球化资源。
作为业内最具成长性的期货公司，银河期货将以国际化的服务理念、精英化的团队、高端的技术平台和良好的风险控制能力，提供最专业、最细致、个性化的期货交易服务，未来的发展目标是致力于打造国内一流的国际化金融投资服务平台。
【我们承诺】
正规劳动合同、五险一金（全额缴纳）、补充医疗、双休、餐补、节假日福利、团队活动奖励、年终奖金、年度健康体检。
【我们期待】
携手所有有梦想、有潜力、肯努力的你，金山银河，共同发展，共同腾飞！
陕西友邦石油工程技术有限公司的经营范围包括：一般经营项目：销售建筑材料（不含木材）、化工材料（不含危险、监控、易制毒化学品）、石油钻采机械设备及配件、仪器仪表、橡胶塑料制品；化工新材料的研发；油气田钻井液、水泥浆、压裂剂、新型油田化学助剂的研发、设计、生产、销售；石油钻井、完井、固井、采油、压裂、酸化、油气水井维修、油气井防腐、输油管线清洗；水处理技术服务、工程施工和现场服务。（以上经营范围除国家规定的专控及前置许可项目外）。
CStone Pharmaceuticals is an innovative, research-driven biopharmaceutical enterprise dedicated to pioneering the development of cutting-edge therapeutic medications. Situated in both Shanghai and Suzhou, the company boasts a leadership team comprised of experienced executives from leading multinational pharmaceutical corporations. In July 2016, CStone disclosed the successful conclusion of its Series A funding round, securing a total investment of $150 million (approximately 975 million RMB). This round was co-invested by three prominent industry investors: Oriza Seed Venture Capital (Oriza Seed), Boyu Capital, and WuXi Healthcare Ventures (WXHV).
With an unwavering commitment to addressing the critical healthcare needs of Chinese patients, CStone's extensive pipeline encompasses five therapeutic areas: oncology, cardiovascular diseases, rheumatoid arthritis, hematology, and autoimmune disorders. The company's strategic focus on immuno-oncology serves as its cornerstone, aiming to propel Chinese research onto the global stage through its world-class research and development capabilities, an innovative drug portfolio, and an open innovation approach.
CStone Pharmaceuticals is a pioneering, research-focused biopharmaceutical company headquartered in Shanghai and Suzhou, China. Its executive team comprises seasoned professionals from top-tier multinational pharmaceutical firms. In July 2016, the company successfully concluded its Series A funding round, attracting a total investment of $150 million (equivalent to approximately 975 million RMB). This round was jointly supported by three distinguished industry investors: Oriza Seed Venture Capital (Oriza Seed), Boyu Capital, and WuXi Healthcare Ventures (WXHV).
Driven by a mission to meet the pressing medical needs of Chinese patients, CStone's comprehensive product pipeline spans across five therapeutic sectors: oncology, cardiovascular diseases, rheumatoid arthritis, hematology, and autoimmune diseases. With immuno-oncology at the heart of its strategic focus, the company aspires to position Chinese research on the global stage, leveraging its world-class research and development expertise, innovative drug portfolio, and an open innovation philosophy.